Compare ITRG & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRG | IVVD |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 543.8M | 437.1M |
| IPO Year | 2017 | 2021 |
| Metric | ITRG | IVVD |
|---|---|---|
| Price | $2.71 | $1.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $5.13 | ★ $8.75 |
| AVG Volume (30 Days) | 2.5M | ★ 2.6M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $67.34 | $61.57 |
| Revenue Next Year | $25.89 | $41.42 |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $1.43 | $0.49 |
| 52 Week High | $4.87 | $3.07 |
| Indicator | ITRG | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 37.94 | 47.51 |
| Support Level | $2.57 | $1.46 |
| Resistance Level | $3.29 | $2.00 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 13.71 | 32.69 |
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.